|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network,
Albert Einstein College of Medicine, Analytical Biological
Services, Barretos Cancer Hospital, Baylor College of Medicine,
Beckman Research Institute of City of Hope; Buck Institute for
Research on Aging; Canada's Michael Smith Genome Sciences Centre;
Harvard Medical School, ; Helen F, et al: Integrated genomic and
molecular characterization of cervical cancer. Nature. 543:378–384.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mossanen M and Gore JL: The burden of
bladder cancer care: Direct and indirect costs. Curr Opin Urol.
24:487–491. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gandhi NM, Morales A and Lamm DL: Bacillus
Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int.
112:288–297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kiselyov A, Bunimovich-Mendrazitsky S and
Startsev V: Treatment of non-muscle invasive bladder cancer with
Bacillus Calmette-Guerin (BCG): Biological markers and simulation
studies. BBA Clin. 4:27–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pichler R, Borena W, Schäfer G, Manzl C,
Culig Z, List S, Neururer S, Von Laer D, Heidegger I, Klocker H, et
al: Low prevalence of HPV detection and genotyping in non-muscle
invasive bladder cancer using single-step PCR followed by reverse
line blot. World J Urol. 33:2145–2151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Metawea B, El-Nashar AR, Kamel I, Kassem W
and Shamloul R: Application of viable bacille Calmette-Guerin
topically as a potential therapeutic modality in condylomata
acuminata: A placebo-controlled study. Urology. 65:247–250. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fayed ST, Amer M, Ammar E and Salam MA:
Local BCG injection administered to patients with flat condyloma of
the cervix. Int J Gynaecol Obstet. 107:253–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Böhle A, Büttner H and Jocham D: Primary
treatment of condylomataacuminata with viable bacillus
Calmette-Guerin. J Urol. 165:834–836. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cappello F: Effect of of cervical
antitumoral immunity activation on CIN. Minerva Ginecol.
43:405–408. 1991.(In Italian). PubMed/NCBI
|
|
11
|
Lu X, Wu L, Liu Z, Xie L and Wang S:
Peripheral blood mononuclear cells inhibit proliferation and
promote apoptosis of HeLa cells following stimulation with Bacillus
Calmette-Guerin. Exp Ther Med. 5:561–566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sonoda T, Sugimura K, Ikemoto SI,
Kawashima H and Nakatani T: Significance of target cell infection
and natural killer cells in the anti-tumor effects of bacillus
Calmette-Guerin in murine bladder cancer. Oncol Rep. 17:1469–1474.
2007.PubMed/NCBI
|
|
13
|
Piaggio F, Kondylis V, Pastorino F, Di
Paolo D, Perri P, Cossu I, Schorn F, Marinaccio C, Murgia D, Daga
A, et al: A novel liposomal Clodronate depletes tumor-associated
macrophages in primary and metastatic melanoma: Anti-angiogenic and
anti-tumor effects. J Control Release. 223:165–177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Geissmann F, Manz MG, Jung S, Sieweke MH,
Merad M and Ley K: Development of monocytes, macrophages, and
dendritic cells. Science. 327:656–661. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 11:232002.PubMed/NCBI
|
|
16
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Biswas SK and Mantovani A: Macrophage
plasticity and interaction with lymphocyte subsets: Cancer as a
paradigm. Nat Immunol. 11:889–896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng X, Turkowski K, Mora J, Brüne B,
Seeger W, Weigert A and Savai R: Redirecting tumor-associated
macrophages to become tumoricidal effectorsas a novel strategy.
Oncotarget. 29:48436–48452. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Q, Tian Y, Zhao X, Jing H, Xie Q, Li
P, Li P, Li D, Yan D and Zhu X: NMAAP1 expressed in BCG-activated
macrophage promotes M1 macrophage polarization. Mol Cells.
38:886–894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Dalen FJ, van Stevendaal M, Fennemann
FL, Verdoes M and Ilina O: Molecular repolarisation of
tumour-associated macrophages. Molecules. 24:92018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mills CD: M1 and M2 macrophages: Oracles
of health and disease. Crit Rev Immunol. 32:463–488. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schiffman M, Doorbar J, Wentzensen N, de
Sanjose S, Fakhry C, Monk BJ, Stanley MA and Franceschi S:
Carcinogenic human papillomavirus infection. Nat Rev Dis Primers.
2:160862016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Martel C, Plummer M, Vignat J and
Franceschi S: Worldwide burden of cancer attributable to HPV by
site, country and HPV type. Int J Cancer. 141:664–670. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stevanovic S, Draper LM, Langhan MM,
Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry
RM, Kammula US, et al: Complete regression of metastatic cervical
cancer after treatment with human papillomavirus-targeted
tumor-infiltrating T cells. J Clin Oncol. 33:1543–1550. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seiwert TY, Burtness B, Mehra R, Weiss J,
Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et
al: Safety and clinical activity of pembrolizumab for treatment of
recurrent or metastatic squamous cell carcinoma of the head and
neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial.
Lancet Oncol. 17:956–965. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morris VK, Salem ME, Nimeiri H, Iqbal S,
Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, et al:
Nivolumab for previously treated unresectable metastatic anal
cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet
Oncol. 18:446–453. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van der Burg SH and Melief CJ: Therapeutic
vaccination against human papilloma virus induced malignancies.
Curr Opin Immunol. 23:252–257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stevanovic S, Pasetto A, Helman SR,
Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff
CA, Rosenberg SA and Hinrichs CS: Landscape of immunogenic tumor
antigens in successful immunotherapy of virally induced epithelial
cancer. Science. 356:200–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang DW, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res.
41:D808–D815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu H, Zhang L and Wang P: Complement
factor H-related 3 overexpression affects hepatocellular carcinoma
proliferation and apoptosis. Mol Med Rep. 20:2694–2702.
2019.PubMed/NCBI
|
|
35
|
Sánchez-Rodríguez C, Cruces KP, Ayora JR,
Martín-Sanz E and Sanz-Fernández R: BCG immune activation reduces
growth and angiogenesis in an in vitro model of head and neck
squamous cell carcinoma. Vaccine. 35:6395–6403. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Honkanen TJ, Tikkanen A, Karihtala P,
Mäkinen M, Väyrynen JP and Koivunen JP: Prognostic and predictive
role of tumour-associated macrophages in HER2 positive breast
cancer. Sci Rep. 9:109612019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang M, McKay D, Pollard JW and Lewis CE:
Diverse functions of macrophages in different tumor
microenvironments. Cancer Res. 78:5492–5503. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
de Vos van Steenwijk PJ, Ramwadhdoebe TH,
Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T,
Kuijjer ML, van Poelgeest MIE, van der Burg SH and Jordanova ES:
Tumor-infiltrating CD14-positive myeloid cells and CD8-positive
T-cells prolong survival in patients with cervical carcinoma. Int J
Cancer. 133:2884–2894. 2013.PubMed/NCBI
|
|
40
|
Jayasingam SD, Citartan M, Thang TH, Zin
AA, Ang KC and Ch'ng ES: Evaluating the polarization of
tumor-associated macrophages into M1 and M2 phenotypes in human
cancer tissue: Technicalities and challenges in routine clinical
practice. Front Oncol. 9:15122019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
English PMB: Eradicating cervical cancer
is unlikely. BMJ. 366:l49532019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Luca S and Mihaescu T: History of BCG
vaccine. Maedica (Bucur). 8:53–58. 2013.PubMed/NCBI
|
|
44
|
Locht C and Lerm M: Good old BCG-what a
century-old vaccine can contribute to modern medicine. J Intern
Med. 12:611–613. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mustafa AS: BCG as a vector for novel
recombinant vaccines against infectious diseases and cancers.
Vaccines (Basel). 84:7362020. View Article : Google Scholar
|
|
46
|
Xue QJ, Li YQ, Yang CQ, Chen T, Li XZ,
Cheng B and Wang CM: Anti-tumour research of recombinant BCG using
BZLF1 and hGM-CSF fusion genes. Vaccine. 14:1599–1607. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kremenovic M, Schenk M and Lee DJ:
Clinical and molecular insights into BCG immunotherapy for
melanoma. J Intern Med. 288:625–640. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Koti M, Morales A, Graham CH and Siemens
DR: BCG vaccine and COVID-19: Implications for infection
prophylaxis and cancer immunotherapy. J Immunother Cancer.
8:e0011192020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Usher NT, Chang S, Howard RS, Martinez A,
Harrison LH, Santosham M and Aronson NE: Association of BCG
vaccination in childhood with subsequent cancer diagnoses A 60-year
follow-up of a clinical trial. JAMA Netw Open. 2:e19120142019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jabbar IA, Fernando GJ, Saunders N,
Aldovini A, Young R, Malcolm K and Frazer IH: Immune responses
induced by BCG recombinant for human papillomavirus L1 and E7
proteins. Vaccine. 18:2444–2453. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Svatek RS, Zhao XR, Morales EE, Jha MK,
Tseng TY, Hugen CM, Hurez V, Hernandez J and Curiel TJ: Sequential
intravesical mitomycin plus Bacillus Calmette-Guerin for
non-muscle-invasive urothelial bladder carcinoma: Translational and
phase I clinical trial. Clin Cancer Res. 21:303–311. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Doorbar J, Egawa N, Griffin H, Kranjec C
and Murakami I: Human papillomavirus molecular biology and disease
association. Rev Med Virol. 25 (Suppl 1):S2–S23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Borges HL, Bird J, Wasson K, Cardiff RD,
Varki N, Eckmann L and Wang JY: Tumor promotion by
caspase-resistant retinoblastoma protein. Proc Natl Acad Sci.
102:15587–15592. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
van den Heuvel S and Dyson NJ: Conserved
functions of the pRB and E2F families. Nat Rev Mol Cell Biol.
9:713–724. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yamazaki-Nakashimada MA, Unzueta A,
Gámez-González LB, González-Saldaña N and Sorensen RU: BCG: A
vaccine with multiple faces. Hum Vaccin Immunother. 16:1841–1850.
2020. View Article : Google Scholar : PubMed/NCBI
|
